This is the authors' abstract. We don't add key points for this paper.
Resistance to cancer therapy continues to be a major limitation for the successful treatment of cancer. There are many published studies on therapy resistance in breast and prostate cancers; however, there are currently no data on molecular markers associated with resistance. The conflicting data were reported regarding the AKT/m-TOR signaling pathway components as markers predicting resistance. The AKT/m-TOR signaling pathway is involved in the development of many human cancers; its activation is related to cell proliferation, angiogenesis, apoptosis, as well as to therapy resistance. Molecular alterations in the AKT/m-TOR signaling pathway provide a platform to identify universal markers associated with the development of resistance to cancer therapy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Спирина et al. (2018) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: